{"disease":{"id":"her2-negative-breast-neoplasms","name":"her2 negative breast neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT06966700","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT01969643","title":"A Safety Study of SGN-LIV1A in Breast Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT05194072","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":250,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04665921","title":"A Study of SGN-STNV in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":111,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04042480","title":"A Study of SGN-CD228A in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":88,"lead_sponsor_name":"Seagen Inc.","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}